ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Transcatheter Arterial Embolization for Non-Variceal Upper Gastrointestinal Bleeding: Does the Number of Prior EGDs Matter?
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Arterial Embolization for Non-Variceal Upper Gastrointestinal Bleeding: Does the Number of Prior EGDs Matter?JGH open : an open access journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Transcatheter arterial embolization (TAE) is an important therapy for non-variceal upper gastrointestinal bleeding (NVUGIB) when endoscopic intervention fails. The impact of repeated esophagogastroduodenoscopies (EGDs) before TAE on clinical outcomes remains unclear. This study aimed to evaluate the association between the number of EGDs before TAE and outcomes including rebleeding, mortality, and hospitalization. Methods: We conducted a retrospective cohort study of adults with NVUGIB undergoing TAE at a single tertiary center (2010-2023). Patients were stratified by the number of pre-TAE EGDs (0, 1, and ≥ 2), embolization strategy (therapeutic, empiric, no embolization), number of embolic agents, and vessel involvement. Primary outcome was 30-day rebleeding; secondary outcomes included in-hospital and 30-day mortality, length of stay, transfusion needs, and cost. Results: Ninety-two patients (median age 68; 52.2% male) were included. Thirty-day rebleeding occurred in 43.3%, and in-hospital mortality was 14.1%. Patients with ≥ 2 EGDs had the longest hospital stay (14.5 vs. 10 vs. 5.5 days; Conclusions: Repeated EGDs before TAE prolonged hospitalization without improving outcomes. Both empiric and therapeutic embolization reduced rebleeding compared with angiography alone. Early referral for TAE after failed endoscopy may optimize NVUGIB management.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.